Herbst Kinsky advises Biogena Group Invest on its capital increase
Following the successful listing of Biogena Group Invest AG on the Vienna Stock Exchange (direct market) in the end of 2020, Herbst Kinsky is now advising its client in the course of its capital increase to approx. 4 million shares. The subscription period for the total of 1,995,000 new shares started on April 12, 2021 and ends on April 26, 2021.
Offer to both existing and new investors
Both existing shareholders and new interested investors can already place orders for subscription. More information, in particular on the subscription procedure: https://biogena-investors-club.com/offering/.
Biogena Group is an operating group of companies in the field of high-quality micronutrients and health, in which Biogena Group Invest AG holds a stake. The business activity of the Biogena Group is the development and distribution of products and services in the field of health and nutrition. The main focus is on iron, mineral and osteoporosis product innovations as well as new integrated solutions in the field of workplace health promotion. The Biogena Group is Austria’s market leader in the field of dietary supplements and high-quality micronutrients, currently employs over 360 people and supplies to over 40 countries worldwide. The last consolidated annual turnover of the Biogena Group was 54 million euros with an E-BITA ratio of over 25%.
“The journey with our client continues and we are particularly proud to accompany this innovative company. Due to its great success, Biogena is expected to move from the “direct market” to the “direct market plus” segment in May 2021,” says Johannes Frank, attorney at Herbst Kinsky.
Herbst Kinsky´s team was led by Johannes Frank supported by Carmen Walser and Georg Durstberger.